Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

5 enrolled

Breast

Breast Neoplasms

NCT05949541 2024-02-08

BCTOP-L-M01

Phase 2 Recruiting

265 enrolled

Breast

Breast Neoplasms

NCT03312738 2024-01-23

BOLERO-5

Phase 2 Completed

159 enrolled 25 charts

Breast

Breast Neoplasms

NCT05954442 2024-01-16

BCTOP-T-M03

Phase 3 Recruiting

203 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

283 enrolled 22 charts

Breast

Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT00934895 2023-09-18

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Phase 1/2 Terminated

27 enrolled 12 charts

Breast

Breast Neoplasms

NCT01298713 2023-09-06

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

Phase 2 Completed

111 enrolled

Breast

Breast Neoplasms

NCT02028364 2023-08-24

PEARL

Phase 2 Completed

55 enrolled

Breast

Breast Neoplasms

NCT00255788 2023-08-04

Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

Phase 2 Completed

49 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01698918 2023-05-03

BOLERO-4

Phase 2 Completed

202 enrolled 19 charts

Breast

Breast Neoplasms

NCT05079360 2023-03-24

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04355858 2022-07-26

MULAN

Phase 2 Unknown

319 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast

Breast Neoplasms

NCT01499160 2022-02-11

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Phase 2 Terminated

7 enrolled 6 charts

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT02236572 2022-02-01

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Phase 2 Terminated

17 enrolled 11 charts

Breast

Breast Neoplasms

NCT05108740 2021-12-09

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

No longer available

Breast

Breast Neoplasms

NCT02742051 2021-09-23

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Phase 2 Completed

40 enrolled

Breast

Breast Neoplasms

Clinical Trials

EVOLVE-BDT

LITESPARK-029

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

SERENA-1

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

POLARIS

e3

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

ELEVATE

AMEERA-1

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

TACTIVE-E

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

EMBER

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

AZD9833

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

abemaSNF1/3

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

VERU-024

BCTOP-L-M01

BOLERO-5

BCTOP-T-M03

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

ROME

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

PEARL

Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

BOLERO-4

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

MULAN

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase II Study of Everolimus Beyond Progression

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer